What Autonomix Medical, Inc. does.

We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (“RF”) ablation, enabling a “sense, treat, verify” approach intended to improve the precision and consistency of nerve-targeted therapies.

The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. By placing signal amplification and digitization at or near the point of detection, this approach is intended to reduce signal degradation and improve detection of neural activity compared to conventional systems. We believe this may enable more precise localization of target nerves and support targeted therapeutic intervention.

Our development efforts are focused on two core components: diagnostic sensing and therapeutic RF ablation. In preclinical studies, our sensing technology has demonstrated the ability to detect signals from specific nerve bundles prior to ablation and confirm signal termination following treatment. We are currently refining the design of our catheter to meet requirements for human use in the United States.

Revenue and profit, by fiscal year.

More on AMIX.

• Autonomix Medical, Inc. summary
• Autonomix Medical, Inc. financial statements
• Autonomix Medical, Inc. key metrics
• Autonomix Medical, Inc. health scores and style box
• Autonomix Medical, Inc. earnings
• Autonomix Medical, Inc. dividends
• Autonomix Medical, Inc. valuation
• Autonomix Medical, Inc. ownership and insiders
• Autonomix Medical, Inc. peers

Figures from Autonomix Medical, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.